Editorial: Influences of diabetes on the development and progression of cardiovascular disease

British Journal of Diabetes and Vascular Disease

Volumn 10, Issue 2, 2010, Pages 54-56

  Schindler, Christoph ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PIOGLITAZONE; ROSIGLITAZONE; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ARTERY CALCIFICATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; EDITORIAL; GLYCOCALYX; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; RISK FACTOR;

EID: 77952527119     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/1474651410367260     Document Type: Editorial

References (21)

1. IDF Diabetes Atlas. 4th edition. Brussels: IDF, 2009;104.
2. Highlander P, Shaw GP. Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics. Ther Adv Cardiovasc Dis 2010;4:43-54.
3. Noble M, Drake-Holland A. Hyperglycaemia and the vascular glycocalyx: the key to microalbuminuria and cardiovascular disease in diabetes mellitus? Br J Diabetes Vasc Dis 2010;10:66-70.
4. Broekhuizen LN, Mooij HL, Kastelein JJ et al. Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease. Curr Opin Lipidol 2009;20:57-62.
5. Singh D, Winocour P, Farrington K. Endothelial cell dysfunction, medial arterial calcification and osteoprotegerin in diabetes. Br J Diabetes Vasc Dis 2010;10:71-77.
6. D'Amelio P, Isaia G, Isaia GC. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. J Endocrinol Invest 2009;32:6-9.
7. O'Donoghue M, Braunwald E. Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol 2010;7:13-20.
8. Toth PP. An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Commentary. J Fam Pract 2009; 58:S41 -3.
9. Noman A, George J, Struthers A. A new use for B-type natriuretic peptide: to detect myocardial ischaemia in non-heart failure patients. Br J Diabetes Vasc Dis 2010;10:78-82.
10. van Wijk DF, Stroes ES, Kastelein JJ. Lipid measures and cardiovascular disease prediction. Dis Markers 2009;26:209-216
11. Kuppuswamy V, Mela M, Eustace I, Gupta S. Meeting UK national targets for lipids in acute coronary syndrome with early and intensive lipid reduction: a single centre district general hospital experience. Br J Diabetes Vasc Dis 2008;8:286-290
12. National Collaborating Centre for Primary Care. NICE clinical guideline 67: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London: NICE, 2008.
13. Morrissey RP, Diamond GA, Kaul S. Statins in acute coronary syndromes: do the guideline recommendations match the evidence? J Am Coll Cardiol 2009;54:1425-1433
14. Devine M, Chandrasekara W, Hardy K. Management of hyperglycaemia in acute coronary syndrome. Br J Diabetes Vasc Dis 2010;10.
15. Kuhlmann M, Marre M. Lessons learned from biosimilar epoetins and insulins. Br J Diabetes Vasc Dis 2010;10:90-97.
16. Triay M, Waheed M. Calciphylaxis. Br J Diabetes Vasc Dis 2010; 10:103-104.
17. Dweck M, Francis M. Three vessel coronary ectasia in patient with previous cerebral malaria. Br J Diabetes Vasc Dis 2010;10:101-102.
18. United States Senate Committee on Finance: Staff report on GlaxoSmithKline and the diabetes drug Avandia. January 2010. http://finance.senate.gov/press/Gpress/2010/prg022010a.pdf (Accessed February 2010).
19. Nissen SE. The rise and fall of rosiglitazone. Eur Heart J 2010 EPub ahead of print. http://eurheartj.oxfordjournals.org/content/early/2010/02/11/ eurheartj.ehq016.extract (Accessed February 2010).
20. Krumholz H. A perspective on the American Heart Association Presidential Commission: advisory on thiazolidinedione drugs. Circ Cardiovasc Qual Outcomes 2010 EPub ahead of print. http://circ.ahajournals.org/cgi/content/abstract/CIR. 0b013e3181d34114v1(Accessed February 2010).
21. Schindler C. The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? Ther Adv Cardiovasc Dis 2007;1:7-26.